Skip to main content
High RiskFDAfda-F-1590-2017UNDECLARED ALLERGEN

Goulibeur- Cube tin box Life in Paris, containing mini heart-shaped pure butter shortbreads Net weight 4.23 oz

Category
Units Affected
800
Recall Date
January 27, 2017
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1590-2017.

This recall has been initiated due to missing information about the presence of the milk allergen in the list of ingredients. It is written that the products contain butter, but the food source for this ingredient (milk) is not indicated.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1590-2017.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Goulibeur or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1590-2017.

GOULIBEUR

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Goulibeur Recall FAQ

Goulibeur is the subject of a dairy safety report: Goulibeur- Cube tin box Life in Paris, containing mini heart-shaped pure butter shortbreads Net weight 4.23 oz. The notice was published on January 27, 2017 by the U.S. Food and Drug Administration (FDA). Approximately 800 units are potentially affected.